LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article: A Case Report of Individualised Homoeopathic Treatment in Molluscum Contagiosum

    Singh, Uttam / Paul, Jiji

    Homœopathic Links

    2021  Volume 34, Issue 03, Page(s) 223–226

    Abstract: Molluscum contagiosum (MC) is the most frequent human disease resulting from poxvirus infection. It has a worldwide distribution. Children are usually affected. There is no specific systemic treatment for MC, but a variety of techniques for physical ... ...

    Abstract Molluscum contagiosum (MC) is the most frequent human disease resulting from poxvirus infection. It has a worldwide distribution. Children are usually affected. There is no specific systemic treatment for MC, but a variety of techniques for physical ablation have been used. Homoeopathic treatment offers an effective and safe treatment with painless management of the MC cases. Here, a 3.6-year-old female child presented with complaints of papular eruptions on the face for the last 1 year. She was effectively treated by individualised homoeopathic medicine Calcarea carbonica. Improvement in the case was assessed by outcome in relation to impact on daily living scale at each month for 05 months during follow-ups and possible causal attribution of the changes in the case was measured using ‘Modified Naranjo Criteria’. This case report showed positive role and efficacy of homoeopathic treatment of MC in children.
    Keywords molluscum contagiosum (MC) ; individualised homoeopathy ; ORIDL ; Naranjo criteria
    Language English
    Publishing date 2021-09-01
    Publisher Thieme Medical and Scientific Publishers Pvt. Ltd.
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 1199312-1
    ISSN 1860-3149 ; 1019-2050
    ISSN (online) 1860-3149
    ISSN 1019-2050
    DOI 10.1055/s-0041-1735486
    Database Thieme publisher's database

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5733: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Validation of a Novel Fluorescent Lateral Flow Assay for Rapid Qualitative and Quantitative Assessment of Total Anti-SARS-CoV-2 S-RBD Binding Antibody Units (BAU) from Plasma or Fingerstick Whole-Blood of COVID-19 Vaccinees.

    Younes, Nadin / Al-Sadeq, Duaa W / Shurrab, Farah M / Zedan, Hadeel T / Abou-Saleh, Haissam / Abo-Halawa, Bushra Y / AlHamaydeh, Fatima M / Elsharafi, Amira E / Daas, Hanin I / Thomas, Swapna / Aboalmaaly, Sahar / Al Farsi, Afra / Al-Buainain, Reeham / Ataelmannan, Samar / Paul, Jiji / Al Saadi, Amana Salih / Yassine, Hadi M / Majdalawieh, Amin F / Ismail, Ahmed /
    Abu-Raddad, Laith J / Nasrallah, Gheyath K

    Vaccines

    2022  Volume 10, Issue 8

    Abstract: Background: Limited commercial LFA assays are available to provide a reliable quantitative measurement of the total binding antibody units (BAU/mL) against the receptor-binding domain of the SARS-CoV-2 spike protein (S-RBD). Aim: This study aimed to ... ...

    Abstract Background: Limited commercial LFA assays are available to provide a reliable quantitative measurement of the total binding antibody units (BAU/mL) against the receptor-binding domain of the SARS-CoV-2 spike protein (S-RBD). Aim: This study aimed to evaluate the performance of the fluorescence LFA FinecareTM 2019-nCoV S-RBD test along with its reader (Model No.: FS-113) against the following reference methods: (i) the FDA-approved GenScript surrogate virus-neutralizing assay (sVNT); and (ii) three highly performing automated immunoassays: BioMérieux VIDAS®3, Ortho VITROS®, and Mindray CL-900i®. Methods: Plasma from 488 vaccinees was tested by all aforementioned assays. Fingerstick whole-blood samples from 156 vaccinees were also tested by FinecareTM. Results and conclusions: FinecareTM showed 100% specificity, as none of the pre-pandemic samples tested positive. Equivalent FinecareTM results were observed among the samples taken from fingerstick or plasma (Pearson correlation r = 0.9, p < 0.0001), suggesting that fingerstick samples are sufficient to quantitate the S-RBD BAU/mL. A moderate correlation was observed between FinecareTM and sVNT (r = 0.5, p < 0.0001), indicating that FinecareTM can be used for rapid prediction of the neutralizing antibody (nAb) post-vaccination. FinecareTM BAU results showed strong correlation with VIDAS®3 (r = 0.6, p < 0.0001) and moderate correlation with VITROS® (r = 0.5, p < 0.0001) and CL-900i® (r = 0.4, p < 0.0001), suggesting that FinecareTM can be used as a surrogate for the advanced automated assays to measure S-RBD BAU/mL.
    Language English
    Publishing date 2022-08-15
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2703319-3
    ISSN 2076-393X
    ISSN 2076-393X
    DOI 10.3390/vaccines10081318
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Dynamics of Anti-S IgG Antibodies Titers after the Second Dose of COVID-19 Vaccines in the Manual and Craft Worker Population of Qatar.

    Bansal, Devendra / Atia, Hassan / Al Badr, Mashael / Nour, Mohamed / Abdulmajeed, Jazeel / Hasan, Amal / Al-Hajri, Noora / Ahmed, Lina / Ibrahim, Rumissa / Zamel, Reham / Mohamed, Almuthana / Pattalaparambil, Hamad / Daraan, Faisal / Chaudhry, Adil / Oraby, Sahar / El-Saleh, Sahar / El-Shafie, Sittana S / Al-Farsi, Affra Faiz / Paul, Jiji /
    Ismail, Ahmed / Al-Romaihi, Hamad Eid / Al-Thani, Mohammed Hamad / Doi, Suhail A R / Zughaier, Susu M / Cyprian, Farhan / Farag, Elmobashar / Farooqui, Habib Hasan

    Vaccines

    2023  Volume 11, Issue 3

    Abstract: There is limited seroepidemiological evidence on the magnitude and long-term durability of antibody titers of mRNA and non-mRNA vaccines in the Qatari population. This study was conducted to generate evidence on long-term anti-S IgG antibody titers and ... ...

    Abstract There is limited seroepidemiological evidence on the magnitude and long-term durability of antibody titers of mRNA and non-mRNA vaccines in the Qatari population. This study was conducted to generate evidence on long-term anti-S IgG antibody titers and their dynamics in individuals who have completed a primary COVID-19 vaccination schedule. A total of 300 male participants who received any of the following vaccines BNT162b2/Comirnaty, mRNA-1273, ChAdOx1-S/Covishield, COVID-19 Vaccine Janssen/Johnson, or BBIBP-CorV or Covaxin were enrolled in our study. All sera samples were tested by chemiluminescent microparticle immunoassay (CMIA) for the quantitative determination of IgG antibodies to SARS-CoV-2, receptor-binding domain (RBD) of the S1 subunit of the spike protein of SARS-CoV-2. Antibodies against SARS-CoV-2 nucleocapsid (SARS-CoV-2 N-protein IgG) were also determined. Kaplan-Meier survival curves were used to compare the time from the last dose of the primary vaccination schedule to the time by which anti-S IgG antibody titers fell into the lowest quartile (range of values collected) for the mRNA and non-mRNA vaccines. Participants vaccinated with mRNA vaccines had higher median anti-S IgG antibody titers. Participants vaccinated with the mRNA-1273 vaccine had the highest median anti-S-antibody level of 13,720.9 AU/mL (IQR 6426.5 to 30,185.6 AU/mL) followed by BNT162b2 (median, 7570.9 AU/mL; IQR, 3757.9 to 16,577.4 AU/mL); while the median anti-S antibody titer for non-mRNA vaccinated participants was 3759.7 AU/mL (IQR, 2059.7-5693.5 AU/mL). The median time to reach the lowest quartile was 3.53 months (IQR, 2.2-4.5 months) and 7.63 months (IQR, 6.3-8.4 months) for the non-mRNA vaccine recipients and Pfizer vaccine recipients, respectively. However, more than 50% of the Moderna vaccine recipients did not reach the lowest quartile by the end of the follow-up period. This evidence on anti-S IgG antibody titers should be considered for informing decisions on the durability of the neutralizing activity and thus protection against infection after the full course of primary vaccination in individuals receiving different type (mRNA verus non-mRNA) vaccines and those with natural infection.
    Language English
    Publishing date 2023-02-21
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2703319-3
    ISSN 2076-393X
    ISSN 2076-393X
    DOI 10.3390/vaccines11030496
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Dynamics of anti-S IgG antibodies titers after the second dose of COVID 19 mRNA and non-mRNA vaccines in the manual and craft worker population of Qatar

    Bansal, Devendra / Atia, Hassan / Al Badr, Mashael / Nour, Mohamed / Abdulmajeed, Jazeel / Hasan, Amal / Al-Hajri, Noora / Ahmed, Lina / Ibrahim, Rumissa / Zamel, Reham / Mohamed, Almuthana / Pattalaparambil, Hamad / Daraan, Faisal / Chaudhry, Adil / Oraby, Sahar / El-Saleh, Sahar / El-Shafie, Sittana S / Al-Farsi, Affra Faiz / Paul, Jiji /
    Ismail, Ahmed / Al-Romaihi, Hamad E. / Al-Thani, Mohammed H / Doi, Suhail A.R. / Zughaier, Susu M / Cyprian, Farhan / Farag, Elmobashar / Farooqui, Habib Hasan

    medRxiv

    Abstract: Background: There is limited sero epidemiological evidence on the magnitude and long-term durability of antibody titers of mRNA and non-mRNA vaccines in the Qatari population. This study was conducted to generate evidence on long-term anti-S IgG ... ...

    Abstract Background: There is limited sero epidemiological evidence on the magnitude and long-term durability of antibody titers of mRNA and non-mRNA vaccines in the Qatari population. This study was conducted to generate evidence on long-term anti-S IgG antibodies titers and their dynamics in individuals who have completed a primary COVID-19 vaccination schedule. Methods: A total of 300 participants who received any of the following vaccines BNT162b2/Comirnaty or mRNA-1273 or ChAdOx1-S/Covishield or COVID-19 Vaccine Janssen/Johnson or BBIBP-CorV or Covaxin were enrolled in our study. All sera samples were tested by chemiluminescent microparticle immunoassay (CMIA) for the quantitative determination of IgG antibodies to SARS-CoV-2, receptor-binding domain (RBD) of the S1 subunit of the spike protein of SARS-CoV-2. Antibodies against SARS-CoV-2 nucleocapsid (SARS-CoV-2 N-protein IgG) were also determined. Kaplan-Meier survival curves were used to compare the time from the last dose of the primary vaccination schedule to the time by which anti-S IgG antibodies titers fell into the lowest quartile (range of values collected) for the mRNA and non-mRNA vaccines. Results: Participants vaccinated with mRNA vaccines had higher median anti-S IgG antibody titers. Participants vaccinated with the mRNA-1273 vaccine had the highest median anti-S-antibody level of 13720.9 AU/mL (IQR 6426.5 to 30185.6 AU/mL) followed by BNT162b2 (median, 7570.9 AU/ml; IQR, 3757.9 to 16577.4 AU/mL); while the median anti-S antibody titer for non-mRNA vaccinated participants was 3759.7 AU/mL (IQR, 2059.7-5693.5 AU/mL). The median time to reach the lowest quartile was 3.53 months (IQR, 2.2-4.5 months) and 7.63 months (IQR, 6.3-8.4 months) for the non-mRNA vaccine recipients and Pfizer vaccine recipients, respectively. However, more than 50% of the Moderna vaccine recipients did not reach the lowest quartile by the end of the follow-up period. Conclusions: This evidence on anti-S IgG antibody titers, their durability and decay over time should be considered for the utility of these assays in transmission dynamics after the full course of primary vaccination.
    Keywords covid19
    Language English
    Publishing date 2022-08-25
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2022.08.24.22279159
    Database COVID19

    Full text online

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top